News

The company announced revenues of $17.2 million for the quarter ended December 31, 2008. This compares to revenues of $19.8 million for the quarter ended December 31, 2007.

The FDA approval is based on results from a multicenter study comparing catheter ablation to drug therapy for the treatment of atrial fibrillation (AFib). In this randomized clinical

Until a permanent successor is appointed, Mr Martin will assume the responsibilities formerly held by John Ahern. Mr Ahern has announced his retirement and has also resigned from

Dr Cope has most recently served as the assistant director for research and head of program research development for The Ohio State University Comprehensive Cancer Center, The James

According to the company, the AirSeal Dynamic Pressure System (DPS) provides access by eliminating mechanical valves from the cannula and facilitating the introduction of multiple laparoscopic instruments through

Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with relapsing aggressive non-Hodgkin’s lymphoma. This program is expected to be initiated by

The agreement comes after a successful implementation where GlaxoSmithKline (GSK) experienced the ease of use that empowers operators, engineers and management to positively affect their overall equipment effectiveness

The trial is being carried out in 30 hormone refractory prostate cancer patients with bone metastases in clinical centers in the US and several European countries. This study

The company will open a Phase I study evaluating safety of the Survivin antagonist during the first quarter of 2009. Survivin is a key protein that controls cancer